David Angulo Selected Research

ibrexafungerp

1/2022	In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study.
1/2021	Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata.
1/2021	In Vitro pH Activity of Ibrexafungerp against Fluconazole-Susceptible and -Resistant Candida Isolates from Women with Vulvovaginal Candidiasis.
9/2020	Oral Ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis.
8/2020	Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections.
1/2020	Penetration of Ibrexafungerp (Formerly SCY-078) at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model.
1/2020	Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.
10/2019	MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis.
1/2019	Clinical Pharmacokinetics and Drug-Drug Interaction Potential for Coadministered SCY-078, an Oral Fungicidal Glucan Synthase Inhibitor, and Tacrolimus.
1/2019	SCY-078, a Novel Fungicidal Agent, Demonstrates Distribution to Tissues Associated with Fungal Infections during Mass Balance Studies with Intravenous and Oral [14C]SCY-078 in Albino and Pigmented Rats.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David Angulo Research Topics

Disease

5	Infections 01/2021 - 01/2017
5	Mycoses (Diseases, Fungus) 01/2020 - 01/2017
4	Invasive Candidiasis 01/2022 - 01/2017
3	Vulvovaginal Candidiasis 01/2021 - 09/2020
2	Body Weight (Weight, Body) 01/2020 - 10/2008
2	Candidiasis (Moniliasis) 01/2020 - 01/2017
2	Invasive Fungal Infections 10/2018 - 10/2008
1	Coccidioidomycosis 10/2022
1	Invasive Pulmonary Aspergillosis 01/2020
1	Lung Injury 01/2020
1	Liver Abscess 01/2020
1	Candidemia 01/2017
1	Parkinson Disease (Parkinson's Disease) 01/2009
1	Neutropenia 10/2008
1	Mucositis 10/2008
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 10/2008
1	Diarrhea 10/2008
1	Vomiting 10/2008
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2008

Drug/Important Bio-Agent (IBA)

13	ibrexafungerpIBA 01/2022 - 01/2017
5	TriterpenesIBA 08/2020 - 01/2017
3	Pharmaceutical PreparationsIBA 10/2022 - 01/2020
3	glucan synthaseIBA 01/2020 - 01/2019
2	EchinocandinsIBA 01/2021 - 10/2019
1	AzolesIBA 01/2021
1	Fluconazole (Zonal)FDA LinkGeneric 01/2021
1	TriazolesIBA 01/2020
1	isavuconazoleIBA 01/2020
1	Sodium Glutamate (Accent)IBA 10/2019
1	Rosiglitazone (Avandia)FDA Link 10/2018
1	GlucansIBA 01/2017
1	Proteins (Proteins, Gene)FDA Link 01/2009
1	alpha-SynucleinIBA 01/2009
1	Proton Pump InhibitorsIBA 10/2008
1	EnzymesIBA 10/2008
1	TransferasesIBA 10/2008
1	posaconazole FDA Link 10/2008

Therapy/Procedure

3	Therapeutics 01/2021 - 10/2019
1	Drug Therapy (Chemotherapy) 10/2008